Filter by content type
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
March 20, 2026 - … Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 … Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 … characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI ® ), an …
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
February 8, 2026 - … Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … “LEQEMBI ® ” (brand name in China: “乐意保 ® ”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, …
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
January 25, 2026 - … FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as … Disease under Priority Review FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as … Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI ® ) subcutaneous …
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
January 5, 2026 - … Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … in China January 5, 2026 News Release General If approved, lecanemab may become the first and only anti-amyloid …
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 8, 2025 - … “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … Commercial Insurance Innovative Drug List “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease … “LEQEMBI ® ” (brand name in China: “乐意保 ® ”, generic name: lecanemab), has been included in the “Commercial Insurance …
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 3, 2025 - … Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s … Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s … aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI ® ) were …
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 2, 2025 - … 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF New Data … 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF December … the latest data confirming the pharmacological effect of lecanemab (generic name, U.S. brand name: LEQEMBI ® ), an …
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
November 27, 2025 - … Japan November 27, 2025 News Release General If approved, lecanemab would be the first and only anti-amyloid treatment … application for “LEQEMBI ® ” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation … multiple subcutaneous (SC) administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD …
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
November 25, 2025 - … Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as … Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as … (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI ® ) subcutaneous …
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
November 20, 2025 - … Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical … on Alzheimer’s Disease Conference Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical … Conference November 20, 2025 News Release General New lecanemab findings highlight the safety and potential …
